Bioregulator EBVBLOX (EPI EBV) for the prevention of Epstein-Barr virus Super Peptide - 90 Veg Capsules
The mechanism of action of EBVBLOX involves activation of pathways that stimulate the proliferation and differentiation of cytotoxic T cells, thereby increasing their population and increasing their ability to detect and neutralize EBV-infected cells. In addition, EBVBLOX has the ability to enhance the production of immune signaling molecules called cytokines, which activate the recruitment and activation of other immune cells. This organized response collectively targets the virus.
Epstein-Barr virus is a very common disease, similar in origin to the well-known herpes virus. In the literature, this virus can be found under the abbreviated form - EBV or VEBI.
It is dangerous because it provokes many diseases of the human body, in particular, the gastrointestinal tract, central nervous system, as well as bacterial and fungal diseases, etc. Infection is fraught with serious complications for the entire body.
Infection occurs through household contact, through saliva during kissing, and also through sexual intercourse.
Once in the body of a healthy person, the Epstein-Barr virus does not manifest itself immediately, but only after a month or two. During this time, it actively multiplies, and then “spreads” through the circulatory system throughout the body.
Symptoms
The external manifestation of infection is expressed by:
- increase in temperature;
- the appearance of chills;
- general weakness;
- enlarged lymph nodes;
- headaches;
- rapid fatigue;
- disruption of the gastrointestinal tract.
Sometimes the presence in the body is asymptomatic.
With a weakened immune system, EBV can develop into one of the chronic forms:
- Erased form. Signs: increase and prolonged retention of body temperature in the range of 37-38 degrees, increased fatigue, pain in muscles and joints, drowsiness, enlarged lymph nodes.
- Active form. Signs: relapse of mononucleosis symptoms (sore throat, fever, lymph inflammation, etc.) with complications due to fungal and bacterial infections. Possible herpetic formations on the skin, damage to the gastrointestinal tract (diarrhea, nausea, abdominal pain).
- Generalized form. Signs: damage to the central nervous system, heart, lungs, liver.
- Atypical form. Signs: relapse of intestinal infections, diseases of the genitourinary system, repeated infections with acute respiratory infections. Diseases, as a rule, are protracted and difficult to treat.
Infectious mononucleosis, known as Filatov's disease, is the most common manifestation of Epstein-Barr. This is a condition of the body similar to a common cold, when the patient complains of a sore throat and fever. A severe form of the disease seriously affects the respiratory tract (even pneumonia) and other internal organs, in particular the liver and spleen. If medical attention is not sought promptly, the infection can be fatal. Children and adolescents are most often affected.
For the treatment of EBV, antiviral therapy (acyclovir) and drugs to strengthen the immune system (immunomodulators, probiotics, vitamins and minerals) are commonly used.
EBVBLOX combines approaches to disrupt gene expression and latency and enhance the immune response to address the complex dynamics of Epstein-Barr virus (EBV) infection.
Epstein-Barr virus (EBV) is capable of entering a latent state in host cells, during which it remains dormant and can then be reactivated, leading to recurrent infections and potential disease progression. The therapeutic action of EBVBLOX is aimed at interfering with the expression of latent genes that allow EBV to surreptitiously persist in the host cell without causing a strong immune response.
EBVBLOX specifically targets viral factors integral to the maintenance of latency, including viral transcription factors (e.g., EBNA1) that control the regulation of latency-associated genes. By disrupting the complex regulatory mechanisms that govern the repression of these genes, EBVBLOX aims to prevent the virus from remaining in host cells for long periods of time. This disruption causes the presentation of viral antigens on the cell surface, thereby prompting the immune system to recognize and target infected cells for destruction.
Moreover, EBVBLOX provides an enhanced immune response against the virus, which is a key aspect of fighting EBV.
The mechanism of action of EBVBLOX involves activation of pathways that stimulate the proliferation and differentiation of cytotoxic T cells, thereby increasing their population and increasing their ability to detect and neutralize EBV-infected cells. In addition, EBVBLOX has the ability to enhance the production of immune signaling molecules called cytokines, which activate the recruitment and activation of other immune cells. This organized response collectively targets the virus.
In this way, EBVBLOX mounts a “multi-pronged offensive” against the virus, preventing its long-term residence in cells while strengthening the immune system’s ability to detect and destroy both latent and reinfected EBV cells.
Adults and children over 12 years old: 1 capsule 3 times a day, 10 minutes before meals.
The course of admission is 1-3 months.
Repeated courses of treatment on the recommendation of a doctor.
EBVBLOX is recommended for use in combination with LYSINE and ProBiotic.
- Taraxacum officinale
- Bionit® EBV
- Galium aparine
- Urtica dioica
- Ganoderma
- Agaricus blazei
- Melissa officinalis
- Peptide Complex
